AI-powered nature-derived drug developer Kapoose Creek Bio has identified two potential lead compounds for neurological diseases and mental health conditions. The company is currently optimizing these compounds through human dosing, with the goal of creating a preclinical drug candidate.

The two compounds, KCB-100 and KCB-200, were extracted from the biotech firm's collection of cultivated and conserved fungi, and have reportedly exhibited potent neuroplastic and neuroprotective activities. The company will leverage its AI platform, unEarth Rx, to isolate and optimize compounds extracted from nature and expedite the drug discovery process.

Kapoose Creek Bio specializes in leveraging AI to discover small-molecule medicines from nature. The company focuses on identifying and developing novel therapeutic compounds derived from cultivated fungal sources. Utilizing its proprietary unEarth Rx platform, Kapoose integrates phenotypic screening with advanced ML to accelerate the identification of drug leads. The company’s studies target several therapeutic areas, including neuroscience, cancer, and infectious diseases​.